Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 253

1.

Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1.

Gui CY, Ngo L, Xu WS, Richon VM, Marks PA.

Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6. Epub 2004 Jan 20.

2.

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.

Richon VM, Sandhoff TW, Rifkind RA, Marks PA.

Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9.

3.
5.

[Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines].

Chen YX, Fang JY, Lu J, Qiu DK.

Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):312-7. Chinese.

PMID:
15059516
6.
7.

5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.

Scott SA, Dong WF, Ichinohasama R, Hirsch C, Sheridan D, Sanche SE, Geyer CR, Decoteau JF.

Leuk Res. 2006 Jan;30(1):69-76. Epub 2005 Jul 25.

PMID:
16043219
8.

Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites.

Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T.

Ann N Y Acad Sci. 1999;886:195-9. Review.

PMID:
10667218
9.

The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene.

Lagger G, Doetzlhofer A, Schuettengruber B, Haidweger E, Simboeck E, Tischler J, Chiocca S, Suske G, Rotheneder H, Wintersberger E, Seiser C.

Mol Cell Biol. 2003 Apr;23(8):2669-79.

10.

Histone deacetylase inhibitors activate p21(WAF1) expression via ATM.

Ju R, Muller MT.

Cancer Res. 2003 Jun 1;63(11):2891-7.

11.

Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects.

Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, Xu H, Cohen D.

J Biol Chem. 1999 Dec 3;274(49):34940-7.

12.

P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.

Hsieh YJ, Hwu L, Chen YC, Ke CC, Chen FD, Wang HE, Lin KP, Yeh HH, Chang CW, Liu RS.

J Nucl Med. 2014 Apr;55(4):678-85. doi: 10.2967/jnumed.113.126573. Epub 2014 Mar 17.

13.
14.

Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis.

Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, Roessner A, Schneider-Stock R.

J Cell Mol Med. 2008 Apr;12(2):607-21. doi: 10.1111/j.1582-4934.2007.00136.x. Erratum in: J Cell Mol Med. 2008 Aug;12(4):1421.

15.

Histone deacetylase inhibitors selectively suppress expression of HDAC7.

Dokmanovic M, Perez G, Xu W, Ngo L, Clarke C, Parmigiani RB, Marks PA.

Mol Cancer Ther. 2007 Sep;6(9):2525-34.

16.
17.
18.

The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.

Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW.

Oncogene. 2014 Nov 20;33(47):5415-23. doi: 10.1038/onc.2013.482. Epub 2013 Dec 2.

PMID:
24292681
19.

A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase.

Myzak MC, Karplus PA, Chung FL, Dashwood RH.

Cancer Res. 2004 Aug 15;64(16):5767-74.

Supplemental Content

Support Center